Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 23;10(1):195.
doi: 10.1038/s41531-024-00804-0.

A review of temporal interference, nanoparticles, ultrasound, gene therapy, and designer receptors for Parkinson disease

A D Currie  1 , J K Wong  2 , M S Okun  2
Affiliations
Review

A review of temporal interference, nanoparticles, ultrasound, gene therapy, and designer receptors for Parkinson disease

A D Currie et al. NPJ Parkinsons Dis. .

Abstract

In this review, we summarize preclinical and clinical trials investigating innovative neuromodulatory approaches for Parkinson disease (PD) motor symptom management. We highlight the following technologies: temporal interference, nanoparticles for drug delivery, blood-brain barrier opening, gene therapy, optogenetics, upconversion nanoparticles, magnetothermal nanoparticles, magnetoelectric nanoparticles, ultrasound-responsive nanoparticles, and designer receptors exclusively activated by designer drugs. These studies establish the basis for novel and promising neuromodulatory treatments for PD motor symptoms.

PubMed Disclaimer

Conflict of interest statement

A.D.C. and J.K.W. declare no financial or non-financial competing interests. A.D.C.’s fellowship is supported by the Davis Rembert Family Foundation. J.K.W.’s research is supported by NIH KL2TR001429. MSO serves as Medical Advisor the Parkinson’s Foundation, and has received research grants from NIH, Parkinson’s Foundation, the Michael J. Fox Foundation, the Parkinson Alliance, Smallwood Foundation, the Bachmann-Strauss Foundation, the Tourette Syndrome Association, and the UF Foundation. MSO’s research is supported by: R01 NS131342 NIH R01 NR014852, R01NS096008, UH3NS119844, U01NS119562. MSO is PI of the NIH R25NS108939 Training Grant. M.S.O. has received royalties for publications with Hachette Book Group, Demos, Manson, Amazon, Smashwords, Books4Patients, Perseus, Robert Rose, Oxford and Cambridge (movement disorders books). M.S.O. is an associate editor for New England Journal of Medicine Journal Watch Neurology and JAMA Neurology. M.S.O. has participated in CME and educational activities (past 12-24 months) on movement disorders sponsored by WebMD/Medscape, RMEI Medical Education, American Academy of Neurology, Movement Disorders Society, Mediflix and by Vanderbilt University. The institution and not MSO receives grants from industry. M.S.O. has participated as a site PI and/or co-I for several NIH, foundation, and industry sponsored trials over the years but has not received honoraria. Research projects at the University of Florida receive device and drug donations.

Figures

Fig. 1
Fig. 1. Temporal interference.
Two electric fields (E1 and E2, represented by black and yellow arrows, respectively) with frequencies f1 and f2 are applied through external scalp electrodes (grey and yellow disks). Electric fields travel from the emitting electrode (near tail of the electric field vectors) to the receiving electrode (near head of the electric field vectors). The two fields intersect at the intended area of neuromodulation (depicted in purple), producing an envelope frequency Δf which can modulate neural activity.
Fig. 2
Fig. 2. Focused ultrasound for blood-brain barrier opening.
Following intravenous injection of microbubbles (grey spheres), sonication with low-intensity focused ultrasound results in transient opening of the blood-brain barrier. This technique facilitates diffusion of drugs (depicted by green spheres) into the brain parenchyma in the sonicated areas.
Fig. 3
Fig. 3. Applications of gene therapy for the treatment of Parkinson disease.
Viral vectors are synthesized (a) and injected neurosurgically into the intended brain region (b), leading to incorporation into the host cell and protein synthesis (c). Applications of gene therapy for Parkinson disease treatment include synthesis of neurotransmitters such as dopamine and GABA, and expression of cell surface receptors including opsins (used for optogenetic and upconversion nanoparticle approaches), thermal receptors (used with magnetothermal nanoparticles, which requires application of an external magnetic field), and novel drug receptors (used in designer receptors exclusively activated by designed drugs, DREADDs). Purple channels represent proteins synthesized through gene therapy techniques.
Fig. 4
Fig. 4. Applications of nanoparticles for Parkinson disease treatment.
Nanoparticles are synthesized (a) and injected neurosurgically into the intended brain region (b), leading to distribution in the extracellular space (c). Applications of nanoparticles for Parkinson disease treatment include upconversion nanoparticles (requires gene therapy for opsin expression), magnetothermal nanoparticles (requires gene therapy for thermoreceptor expression and application of an external magnetic field), magnetoelectric nanoparticles (requires application of an external magnetic field), and ultrasound-responsive nanoparticles. Purple channels are generated using gene therapy techniques; blue channels are native transmembrane proteins. *Ultrasound-responsive nanoparticles can be administered orally or intravenously and do not require stereotactic injection.
See this image and copyright information in PMC

References

    1. Ou, Z. et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s disease in 204 countries/territories from 1990 to 2019. Front. Public Health9, 776847 (2021). - PMC - PubMed
    1. Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord.30, 1591–1601 (2015). - PubMed
    1. Schapira, A. H. V., Chaudhuri, K. R. & Jenner, P. Non-motor features of Parkinson disease. Nat. Rev. Neurosci.18, 435–450 (2017). - PubMed
    1. Armstrong, M. J. & Okun, M. S. Diagnosis and treatment of Parkinson disease: a review. JAMA323, 548–560 (2020). - PubMed
    1. Pringsheim, T. et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: a report of the AAN guideline subcommittee. Neurology97, 942–957 (2021). - PMC - PubMed

LinkOut - more resources